Which anti-tumor drugs will be included in the 2020 health care negotiations?

With the release of the health-care catalog in 2020, a new round of health-care negotiations is officially over.
two days ago, we made a relevant analysis of the overall adjustment situation, today we would like to talk about the more concerned about the anti-cancer drug negotiations into the health care situation.
(note: This article statistics are only the varieties entered into this negotiation, according to the medical insurance classification "anti-tumor drugs and immunomodulants" this category statistics) According to the pharmaceutical cloud studio statistics, "anti-tumor drugs and immunomodulants" this category added a total of 37 varieties, including 22 new inclusions, 14 new contracts, 1 original health insurance catalog to negotiate varieties.
only five varieties are open to the public, and the rest are confidential.
fluoromarini (new): 65 yuan (0.2g/piece), 38.24 yuan (0.1g/piece); Ni (renewal): 224.99 yuan (8mg/granules), 266.90 yuan (10mg/granules), 306.88 yuan (12mg/granules); 160 yuan (200mg/piece), 272 yuan (400mg/piece); Peimen Dong enzyme (renewal): 1477.7 yuan (2ml:1500IU/branch), 2980 yuan (5ml:3750IU/branch); the specific new varieties are as follows (does not include the negotiated renewal and the original medical insurance catalog to negotiate varieties): all three domestic PD-1 successfully included in the health insurance catalogue This PD-1/L1 negotiation situation is also highly concerned by the industry.
the final three domestic varieties of all successful negotiations, coupled with last year's successful entry into the health insurance catalog of Ida Bio's Daboshu, four domestic PD-1 all included in the health insurance.
price of the three PD-1s was not announced, CCTV news reports showed a "80% reduction in PD-1 inhibitors."
This also the price of PD-1 from the "unaffordable" 300,000 yuan / year, directly pulled to about 100,000 yuan / year, even the U.S. FDA is calling out: welcome Chinese pharmaceutical companies to bring low-cost PD-1/PD-L1 to the United States.
This health care catalog negotiations, 7 related products are all shortlisted, the competition can be described as extremely fierce, Hengrui Pharmaceuticals, Baiji Shenzhou, Junshi Bio 3 local pharmaceutical companies will be with Merca East, BMS, AZ and other 4 multinational giants face-to-face.
According to statistics, the first half of domestic PD-1 sales of about 3.7 billion yuan, coupled with imports of K-drugs (Mershadong company, last year's domestic sales of more than 2 billion yuan), O-drugs (BSM hundred-time Meishi Shiguibao Company), this year's PD-1 market space has been more than 10 billion.
health insurance is an important boost for PD-1 mono-resistance.
to Xinda Bio's Xindili mono-resistance as an example, with health insurance reimbursement of the excellent sales volume is obvious.
the company's financial results, Dabershu's sales in the first six months of 2020 reached 920.9 million yuan, up 177.7 percent year-on-year.
sales in the first three quarters of 2020 exceeded 1.5 billion yuan.
industry has previously analyzed that the 2020 PD-1/L1 health care negotiations will face a more complex situation than in 2019.
1 is a significant increase in the number of players involved in the health care negotiations this year, such as the 2019 health care negotiations of Hengrui Pharmaceutical's Karelli Zhu single resistance, Baiji Shenzhou's Tyrelli Pearl single resistance, and Roche's Atili Zhu single resistance, AstraZeneca's Dovaliyu single resistance and other products have joined the competition.
is the same adaptive, there are several PD-1s that can be auctioned simultaneously.
In the case of Hodgkin's lymphoma adaptation, Hengrui Pharmaceuticals and Baiji Shenzhou will be able to compete, 2019 into the health insurance of Cymru bioPD-1 or face a "threat";
attached: seven PD-1/L1 products before the basic situation of lunvatinib another noteworthy variety is last year without health insurance lunvatinib, this time also negotiated successfully.
Lenvatinib is a multi-target kinase inhibitor developed by Japan's Aodes that can target a range of regulatory factors, including VEGFR1-3, FGFR1-4, PDGFR alpha, KIT, RET, and more.
September 2018, lenphatinistinist has been approved in China for the treatment of non-excisible hepatocellular carcinoma that has not previously been treated by the systemic system.
november 9, 2020, the second adaptive disorder was approved by the State Drug Administration for the treatment of differentiated thyroid cancer (DTC) patients.
according to public data, the price of lunvatinini has been announced, the specific price of 16800 / box, each box 30 grains, 4mg / grain.
need to point out that the specifications of Lunvatini in China are different from those of Hong Kong, Macao and other countries.
in China, lunvatini is only 4mg/granules, a box of 30 grains, no 10mg/granules specifications.
it is understood that the charitable assistance policy has been established to help patients to a large extent to reduce the financial pressure to pay, so that more patients can afford.
specific policy is: Low-insured patients: free access to assistance.
low-income patients: (2 plus 2) plus (2 plus X), X is the number of months less than or equal to 10, depending on the progress of the individual disease.
assistance model ultimately prevails on the project website publication policy.
patients weighing less than 60 kg (two capsules a day, two boxes a month) enter the assistance program, the annual medication only needs to be purchased for 4 months, which is the average monthly cost of 16800 x 2 x 4/12 x 11200 yuan!!! This fee, compared with the surrounding prices, is really cost-effective.
said that, when it counts as a charitable aid policy, Le Wei Ma spends about 150,000 a year.
therefore, in 2019 the inclusion of lunvatinie in health insurance has assumed the majority of liver cancer patients strong voice and expectations.
in the health-care negotiations has also become one of the most high-profile drugs for all patients.
, however, the negotiations ultimately failed, and Lunvardini had no health insurance catalogue.
and the success of this negotiation is a good thing.
is more concerned about yew alcohol lipids for chemotherapy drugs.
this time the yew alcohol lipid body is also in the health care negotiations list.
Efir alcohol lipid system agent - lipotin® is a patented yew alcohol preparation yew alcohol preparation, the use of innovative lipids for non-small cell lung cancer, ovarian cancer, breast cancer and other types of cancer chemotherapy.
currently, Lipoquinol ® the world's first and only approved yew alcohol lipid product in China.
according to IQVIA, ® is the second largest domestic anti-cancer drug in China in the first half of 2020 and the most commonly used yew alcohol products in China in the first half of 2020.
Previously, yew alcohol lipids have been included as a first-line drug in the CSCO Guidelines for Breast Cancer Diagnosis and Treatment (2020), CSCO Primary Lung Cancer Guidelines (2019), and included in the Expert Consensus on Clinical Application of Pythyexual Drugs for Gynaecological Malignant Tumors and the Expert Consensus on Clinical Application of Yew Drugs in Breast Cancer (2020).
In addition, yew alcohol lipids as a number of chemotherapy preferred combination drugs selected in the "China esophageal cancer radiation therapy guidelines (2019 edition)" Yew alcohol lipids into the medical insurance negotiations list, the restrictions are: first-line chemotherapy for ovarian cancer and later treatment of ovarian metastatic cancer, as a first-line chemotherapy, can also be used in combination with cisplatin;
can be combined with cisplatin for first-line chemotherapy in patients with non-small cell lung cancer who cannot be operated on or radiotherapy.
addition, the domestic 3rd generation EGFR-TKI Amedini negotiated successful access to health insurance, Amethini health insurance payment standard of 176 yuan (55 mg/piece), limited to the use of EGFR-20T790M mutation of late NSCLC patients.
the other PARP inhibitor, Nirapali, also managed to break through into the health-care catalog.